Catalyst Pharmaceuticals Inc’s filing revealed that its Chief Commercial Officer Del Carmen Jeffrey unloaded Company’s shares for reported $0.12 million on Jun 07 ’24. In the deal valued at $16.07 per share,7,541 shares were sold. As a result of this transaction, Del Carmen Jeffrey now holds 18,427 shares worth roughly $0.32 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, INGENITO GARY sold 80,000 shares, generating $1,292,800 in total proceeds. Upon selling the shares at $16.16, the Chief Med. & Reg. Officer now owns 51,391 shares.
Before that, Daly Richard J sold 17,323 shares. Catalyst Pharmaceuticals Inc shares valued at $276,735 were divested by the President and CEO at a price of $15.97 per share. As a result of the transaction, Daly Richard J now holds 234,824 shares, worth roughly $4.13 million.
Citigroup initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to a Buy in a research note published on March 14, 2024; the price target was $27. A number of analysts have revised their coverage, including BofA Securities’s analysts, who began to cover the stock in early March with a ‘”a Buy”‘ rating. Oppenheimer began covering CPRX with “an Outperform” recommendation on December 21, 2023. ROTH Capital revised its rating on August 24, 2022. It rated CPRX as “a Neutral” which previously was an “a Buy”.
Price Performance Review of CPRX
On Friday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock jump 1.27% to $17.59. Over the last five days, the stock has gained 3.84%. Catalyst Pharmaceuticals Inc shares have risen nearly 4.64% since the year began. Nevertheless, the stocks have risen 32.16% over the past one year. While a 52-week high of $17.99 was reached on 07/24/24, a 52-week low of $11.55 was recorded on 02/08/24. SMA at 50 days reached $16.05, while 200 days put it at $15.00. A total of 0.65 million shares were traded, compared to the trading of 1.1 million shares in the previous session.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 17.36, which if violated will result in even more drops to 17.13. On the upside, there is a resistance level at 17.84. A further resistance level may holdings at 18.09. The Relative Strength Index (RSI) on the 14-day chart is 69.39, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.68, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 14.26%. Stochastics%K at 82.58% indicates the stock is a selling.
The most recent change occurred on September 21, 2018 when Cantor Fitzgerald began covering the stock and recommended ‘”an Overweight”‘ rating.
